The Diamonds Study
The overall aim of DIAMONDS is to design new diagnostic tests that can tell quickly and accurately what illness a patient has when they come to hospital with common symptoms such as fever. This would help the right treatment to be given to the right patient, at the right time. This is called 'personalised medicine'. The diagnostic device is called 'personalised medicine signature device' (PMSD).
The RECOVERY Trial
This international clinical trial aims to identify treatments that may be beneficial for people hospitalised with suspected or confirmed COVID-19 or PIMS-TS
BATS Study (Best available Treatments)
Our Best Available Treatments Study (BATS) was a massive, multi-national observational study in which we gathered anonymised data from over 600 patients, looking at their symptoms, what treatments they were given and their outcomes in an effort to see which approaches worked best.
“At Imperial College, we are collaborating as part of an NIH-funded study in the US called PreEVAIL, which is looking at diagnostic and prognostic indicators. Excitingly, we have identified a unique transcriptomic signature for children with PIMS, which is essentially a picture of how your immune system is activated at a cellular level. This will help us to develop diagnostic tools to distinguish the condition from other febrile conditions in children. We are validating this at the moment with samples from the UK, Europe and the US, but it could translate into a point-of-care test” Elizabeth Whittaker
The CLoCK study
“As part of the CLoCk study, we’ve asked children in the community who’ve had confirmed COVID, and also those who’ve not, to complete a questionnaire telling us about how they feel, their symptoms and experiences, and their emotional wellbeing.” Elizabeth Whittaker
Covid-19 complications in children: What we’ve learnt about PIMS and Long Covid. Elizabeth Whittaker
Research into increased levels of the biomarker osteopontin in COVID-19 and PIMS-S patients